Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Phases › Phase 1

Phase 1 (116 companies)

Companies with at least one active program at Phase 1.

Ticker Company Therapeutic areas Phase 1 programs Lead stage Programs
ABSI Absci DermatologyGI/Hepatology+1 3 Phase 1 7
ACIU AC Immune Neurology Rare 4 Phase 3 11
ACRS Aclaris Therapeutics DermatologyRespiratory 2 Phase 2 7
ACRV Acrivon Therapeutics Oncology 2 Phase 2 5
ACTU Actuate Therapeutics Oncology 7 Phase 2 8
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 4
ADAG Adagene Oncology 3 Phase 2 9
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved 10
AKTS Aktis Oncology Oncology 8 Phase 1 9
ALDX Aldeyra Therapeutics DermatologyOncology+1 Rare 1 NDA Submitted 8
ALLO Allogene Therapeutics ImmunologyOncology Rare 4 Phase 2 12
DRTS Alpha Tau Medical Oncology 1 Phase 2 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 5
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 3 Approved 6
ANNX Annexon HematologyNeurology+2 Rare 2 NDA Submitted 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 5 Phase 2 9
APVO Aptevo Therapeutics Oncology 2 Phase 1 8
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 6
ARTV Artiva Biotherapeutics DermatologyImmunology+2 Rare 5 Phase 2 16
ARVN Arvinas NeurologyOncology Rare 9 Approved 15
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 9 Approved 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 5 Phase 1 7
BCAX Bicara Therapeutics Oncology 3 Phase 3 4
BIOA BioAge Labs CardiovascularOphthalmology 2 Phase 1 2
BMEA Biomea Fusion Metabolic 2 Phase 2 5
BCTX BriaCell Therapeutics Oncology 1 Phase 3 8
BBOT BridgeBio Oncology Therapeutics Oncology 8 Phase 1 8
CCCC C4 Therapeutics Oncology 1 Phase 2 2
CABA Cabaletta Bio DermatologyImmunology+2 Rare 8 Phase 1 8
CRBU Caribou Biosciences Oncology 3 Phase 3 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 2 Phase 3 4
CLDX Celldex Therapeutics DermatologyImmunology+1 1 Phase 3 7
CLRB Cellectar Biosciences Oncology 2 Approved 11
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 5 Phase 1 11
CLYM Climb Bio HematologyImmunology+1 Rare 4 Phase 2 7
COGT Cogent Biosciences HematologyOncology Rare 3 NDA Submitted 6
CGEN Compugen Oncology 2 Phase 3 7
CNTB Connect Biopharma Respiratory 2 Phase 2 4
CBIO Crescent Biopharma Oncology 9 Phase 1 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 2 Approved 6
CUE Cue Biopharma Oncology 2 Phase 1 4
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 8 NDA Submitted 10
CTMX CytomX Therapeutics Oncology 2 Phase 1 3
DYN Dyne Therapeutics MetabolicNeurology Rare 1 NDA Submitted 10
ELTX Elicio Therapeutics Oncology 2 Phase 2 6
ELOX Eloxx Pharmaceuticals Renal Rare 2 Phase 2 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 2 Phase 3 6
ERAS Erasca Oncology 3 Phase 1 4
ETON Eton Pharmaceuticals GI/HepatologyMetabolic+1 Rare 1 Approved 14
EXEL Exelixis CardiovascularOncology 5 Approved 21
FHTX Foghorn Therapeutics Oncology 1 Phase 1 1
FBRX Forte Biosciences DermatologyGI/Hepatology 2 Phase 2 3
GUTS Fractyl Health Metabolic 1 Phase 3 3
GHRS GH Research NeurologyWomen's Health 1 Phase 2 4
GRCE Grace Therapeutics Neurology Rare 2 NDA Submitted 3
IMTX Immatics Oncology 7 Phase 2 8
IMRX Immuneering Oncology 3 Phase 3 5
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 4
IBRX ImmunityBio Infectious DiseaseOncology 5 NDA Submitted 16
IMNM Immunome Oncology 6 NDA Submitted 9
INAB IN8bio ImmunologyOncology 2 Phase 2 6
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 6
JANX Janux Therapeutics Oncology 2 Phase 1 2
KPRX Kiora Pharmaceuticals Ophthalmology Rare 1 Phase 2 5
KURA Kura Oncology MetabolicOncology 6 Approved 9
KYMR Kymera Therapeutics DermatologyRespiratory Rare 2 Phase 2 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 3 NDA Submitted 7
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 3 Phase 1 8
MRKR Marker Therapeutics Oncology 4 Phase 1 4
MDNAF Medicenna Therapeutics Oncology 2 Phase 3 9
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 7
GLUE Monte Rosa Therapeutics CardiovascularDermatology+2 Rare 6 Phase 1 8
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 2 11
NGEN NervGen Pharma Neurology 1 Phase 1 4
NKTX Nkarta ImmunologyNeurology+1 Rare 7 Phase 1 7
NBP NovaBridge Biosciences OncologyOphthalmology 4 Phase 2 6
NRIX Nurix Therapeutics ImmunologyNeurology+1 10 Phase 2 15
NVCT Nuvectis Pharma Oncology 3 Phase 1 3
OCGN Ocugen Infectious DiseaseOphthalmology Rare 5 Phase 3 13
OMER Omeros HematologyNeurology+2 Rare 3 NDA Submitted 7
IRD Opus Genetics Ophthalmology Rare 3 Approved 12
ORKA Oruka Therapeutics DermatologyImmunology Rare 1 Phase 2 6
OVID Ovid Therapeutics Neurology Rare 5 Phase 1 6
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 4
CATX Perspective Therapeutics Oncology 4 Phase 1 4
PHIO Phio Pharmaceuticals Oncology 3 Phase 1 4
PMN ProMIS Neurosciences Neurology Rare 1 Phase 1 6
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved 13
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 2 Approved 4
SGMT Sagimet Biosciences DermatologyMetabolic 2 Phase 3 5
SANA Sana Biotechnology MetabolicOncology 1 Phase 1 5
SRPT Sarepta Therapeutics Neurology Rare 3 Approved 10
SCYX Scynexis Infectious Disease 2 Approved 4
SLDB Solid Biosciences CardiovascularNeurology Rare 2 Phase 3 6
GPCR Structure Therapeutics MetabolicRespiratory Rare 2 Phase 2 5
STRO Sutro Biopharma Oncology 1 Phase 1 4
TNGX Tango Therapeutics Oncology 5 Phase 1 6
TECX Tectonic Therapeutic Cardiovascular Rare 1 Phase 2 3
TGTX Tg Therapeutics Neurology Rare 2 Approved 4
TYRA Tyra Biosciences MetabolicOncology Rare 2 Phase 2 5
RARE Ultragenyx Pharmaceutical CardiovascularGI/Hepatology+2 Rare 1 Approved 12
UNCY Unicycive Therapeutics Renal 1 NDA Submitted 2
QURE uniQure HematologyMetabolic+1 Rare 5 Approved 6
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 5 Approved 26
VKTX Viking Therapeutics GI/HepatologyMetabolic+1 Rare 1 Phase 3 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare 8 Phase 3 10
VRDN Viridian Therapeutics Ophthalmology 3 Approved 6
VYGR Voyager Therapeutics MetabolicNeurology Rare 1 Phase 1 7
VTVT vTv Therapeutics MetabolicRespiratory Rare 1 Phase 3 8
WVE Wave Life Sciences MetabolicNeurology+1 Rare 3 Phase 2 5
XNCR Xencor HematologyImmunology+4 Rare 13 Approved 30
XENE Xenon Pharmaceuticals Neurology 3 Phase 3 6
ZBIO Zenas BioPharma DermatologyImmunology+1 Rare 1 NDA Submitted 11
ZURA Zura Bio DermatologyImmunology Rare 1 Phase 2 4
ZYME Zymeworks OncologyRespiratory 4 Approved 11